/
Other
Oral
50
Pipeline Programs↗
34
Active Trials↗
163
Companies Involved↗
Oral is a moderately active landscape with 50 programs across 163 companies. The most active players are Vertex Pharmaceuticals, Grace Therapeutics Inc., Arbutus Biopharma Corporation. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical30
Phase 115
Phase 23
Approved
No programs
Analysis
Trial Status
939
clinical trials
Completed794 · 85%
Terminated45 · 5%
Unknown status43 · 5%
Recruiting21 · 2%
Withdrawn19 · 2%
Active, not recruiting6 · 1%
Other11 · 1%
Clinical Trials
Trial Activity
939 trials
Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography
Recruiting·—·N/A·NCT07383571·102 enrolled
Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
Recruiting·—·N/A·NCT07110207·20 enrolled
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Recruiting·—·Phase 2·NCT04804007·64 enrolled
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
Recruiting·—·Phase 4·NCT06045429·160 enrolled
Page 1 of 63
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)